» Articles » PMID: 16917142

Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)

Overview
Journal Breast Dis
Publisher Sage Publications
Date 2006 Aug 19
PMID 16917142
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Endocrine therapy that targets the estrogen receptor (ER) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer. The selective ER modulator (SERM) tamoxifen has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of ER-positive disease. Tamoxifen blocks the action of estrogen by binding to the ER, and possesses both ER-agonist and antagonist properties. Unfortunately, long-term use of tamoxifen is associated with several important concerns including an increased risk of endometrial cancer and thromboembolic complications. In addition, many patients who initially respond to tamoxifen eventually relapse with resistant disease. New treatment approaches are therefore required. A number of alternative SERMs have been tested as substitutes for tamoxifen. These include; toremifene, droloxifene, idoxifene, and keoxifene. Unfortunately, the SERMs have not proved to be more effective than tamoxifen for the treatment of advanced breast cancer and have shown a high level of cross-resistance with tamoxifen. The subsequent development of the aromatase inhibitors (AIs) is an important therapeutic advance by creating a "no estrogen" environment. Another approach is the development of pure antiestrogens. Fulvestrant is a novel ER antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects. It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or aromatase inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy. This review article discusses the significant and continuing value of SERMs for the treatment of postmenopausal ER-positive breast cancer.

Citing Articles

Dialyl-sulfide with trans-chalcone prevent breast cancer prohibiting SULT1E1 malregulations and oxidant-stress induced HIF1a-MMPs induction.

Nazmeen A, Maiti S, Maiti S Genes Cancer. 2024; 15:41-59.

PMID: 39132498 PMC: 11315411. DOI: 10.18632/genesandcancer.237.


PredTAD: A machine learning framework that models 3D chromatin organization alterations leading to oncogene dysregulation in breast cancer cell lines.

Chyr J, Zhang Z, Chen X, Zhou X Comput Struct Biotechnol J. 2021; 19:2870-2880.

PMID: 34093998 PMC: 8142020. DOI: 10.1016/j.csbj.2021.05.013.


Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target.

Caciolla J, Bisi A, Belluti F, Rampa A, Gobbi S Molecules. 2020; 25(22).

PMID: 33207783 PMC: 7696276. DOI: 10.3390/molecules25225351.


Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines.

Sonehara N, Lacerda J, Jardim-Perassi B, de Paula Jr Jr R, Moschetta-Pinheiro M, Souza Y Oncol Lett. 2019; 17(2):1635-1645.

PMID: 30675223 PMC: 6341749. DOI: 10.3892/ol.2018.9758.


Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.

Krishna B, Chaudhary S, Mishra D, Naik S, Suklabaidya S, Adhya A BMC Cancer. 2018; 18(1):607.

PMID: 29843638 PMC: 5975398. DOI: 10.1186/s12885-018-4528-x.